Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
34,310,812
-
Share change
-
-1,571,097
-
Total reported value
-
$63,468,853
-
Put/Call ratio
-
4.1%
-
Price per share
-
$1.85
-
Number of holders
-
83
-
Value change
-
+$5,857,432
-
Number of buys
-
40
-
Number of sells
-
39
Institutional Holders of JOUNCE THERAPEUTICS INC - COM (JNCE) as of Q1 2023
As of 31 Mar 2023,
JOUNCE THERAPEUTICS INC - COM (JNCE) was held by
83 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
34,310,812 shares.
The largest 10 holders included
TANG CAPITAL MANAGEMENT LLC, Deep Track Capital, LP, Tudor Investment Corp Et Al, Opaleye Management Inc., BlackRock Inc., VANGUARD GROUP INC, Erste Asset Management GmbH, JPMORGAN CHASE & CO, BML Capital Management, LLC, and Ardent Capital Management, Inc..
This page lists
83
institutional shareholders reporting positions in this security
for the Q1 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.